EDMONTON, Jan. 22 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS. The trial, named MAESTRO-01, will include approximately 550 patients at 48 trial sites in 10 countries. The Company remains on track to receive interim data in mid-2008 from the first 200 patients enrolled, when they have completed the 24 months of treatment.
